Eling Pharmaceutical (002603): Short-term performance is under pressure, and non-respiratory products are growing steadily
Eling Pharmaceutical (002603) Company Information Update Report: Short-term business performance is under pressure, innovative attributes help long-term development
Eling Pharmaceutical (002603): Performance is in line with expectations, go to the game lightly and start again
Eling Pharmaceutical (002603): Under pressure from 23 and 1Q24 results, it is expected to improve quarter by quarter
Eling Pharmaceutical (002603) 2023 Third Quarter Report Review: Short-term performance under pressure, R&D has been fruitful
Yiling Pharmaceutical (002603): Short-term performance under pressure, R&D pipeline enters the implementation period
Yiling Pharmaceutical (002603): Short-term performance under pressure, patent Chinese medicine research and development continues to advance
Yiling Pharmaceutical (002603): Short-term R&D work in the respiratory sector continues to advance under pressure
Eling Pharmaceutical (002603): Short-term performance under pressure, insisting on innovative drug research and development to tap endogenous growth potential
Eling Pharmaceutical (002603) 2023 Third Quarter Report Review Report: Steady growth in the first three quarters is optimistic about the company's long-term development
Eling Pharmaceutical (002603): Lianhua drags down the steady state of mind, and academics are welcoming results again
Eling Pharmaceutical (002603): COVID-19 performance continues to be digested, and innovative products are expected to continue to grow
Yiling Pharmaceutical (002603): Short-term performance under pressure, continuous implementation of innovative achievements
Research Report Nuggets 丨 Haitong Securities: In the future, Eling Pharmaceutical will launch a number of innovative traditional Chinese medicine drugs one after another, maintaining a “superior to the market” rating
Eling Pharmaceutical (002603): Non-respiratory products resume growth and development of patented traditional Chinese medicine continues to advance
Eling Pharmaceutical (002603): Non-respiratory products resume growth and development of patented traditional Chinese medicine continues to advance
Eling Pharmaceutical (002603): Cardiovascular and cerebrovascular stability second-line varieties are expected to be gradually released
Eling Pharmaceutical (002603): Maintains the lead in core areas and continues to grow at a high profit side
Eling Pharmaceutical (002603): Performance in the first half of the year is in line with expectations, innovation drives long-term high-quality development
Eling Pharmaceutical (002603): Performance is in line with expectations, cardiovascular and other products are recovering steadily
No Data